Abstract
There is no Food and Drug Administration-approved dedicated transcatheter heart valve to treat native aortic regurgitation. Currently available data from ongoing clinical trials and compassionate use experiences in the United States provide echocardiographic and clinical outcomes to 1-year postprocedure. The case presents a 28-year-old man with severe aortic regurgitation successfully treated with J-Valve in 2019 (JC Medical, Inc). Long-term (5-year) outcomes demonstrate sustained valve hemodynamics and clinical stability, highlighting J-Valve as a promising minimally invasive alternative to surgery for high-risk patients with native aortic regurgitation.